TNFSF11 and osteoporosis: Pharmacologic treatment for osteosarcopenia remains to be developed; however, denosumab, a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, was recently reported to improve not only BMD but also muscle mass and strength in postmenopausal women with osteoporosis [35].